Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITCL: Mitoxantrone and Clofarabine in Refractory/Relapsed Acute Leukemia or NHL
NCT01842672Phase 2Completed
- Sponsor
- New York Medical College
- Start
- Mar 2013
- Primary completion
- Aug 2021
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of clofarabine, mitoxantrone in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphoblastic lymphoma (LL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), sponsored by New York Medical College. Started Mar 2013; status: completed.
02
Drugs
clofarabinemitoxantrone
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)lymphoblastic lymphoma (LL)diffuse large B-cell lymphoma (DLBCL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT01842672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842672.